Get the Stockscreener App
3.76
2.08%
-0.08
Atai Beckley N V stock is traded at $3.76, with a volume of 2.91M.
It is down -2.08% in the last 24 hours and down -34.84% over the past month.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
See More
Previous Close:
$3.84
Open:
$3.86
24h Volume:
2.91M
Relative Volume:
0.49
Market Cap:
$1.37B
Revenue:
$2.59M
Net Income/Loss:
$-137.89M
P/E Ratio:
-4.642
EPS:
-0.81
Net Cash Flow:
$-69.76M
1W Performance:
-4.33%
1M Performance:
-34.84%
6M Performance:
+82.52%
1Y Performance:
+123.81%
1-Day Range:
$3.60
$3.86
1-Week Range:
$3.60
$4.08
52-Week Range:
$1.15
$6.75
Atai Beckley N V Stock (ATAI) Company Profile
Name
Atai Beckley N V
Sector
Industry
Phone
49 89 2153 9035
Address
PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN
Compare ATAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Atai Beckley N V
|
3.76 | 1.39B | 2.59M | -137.89M | -69.76M | -0.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atai Beckley N V Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Atai Beckley N V Stock (ATAI) Latest News
H.C. Wainwright Maintains Buy on Atai Beckley (ATAI) Following Breakthrough Therapy and Merger Completion - Insider Monkey
AtaiBeckley advances BPL-003 toward Phase 3 After Strong Phase 2 Data topline data i - Proactive financial news
Enhanced (ATAI) overhauls leadership, appoints new CEO, executive chairman and CFO - Stock Titan
Atai Beckley N.V. (ATAI) Receives Buy Rating on BPL-003 Edge against Spravato - MSN
H.C. Wainwright reiterates Buy rating on atai Life Sciences stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on atai Life Sciences stock - Investing.com India
AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London - The Manila Times
AtaiBeckley (NASDAQ: ATAI) London fireside chat at 11:30 GMT; replay for 90 days - Stock Titan
AtaiBeckley advances clinical pipeline, strengthens balance sheet in Q3 - Proactive financial news
Atai Beckley Q3 Loss Widens, Revenue Rises; Shares Down Pre-Bell - MarketScreener
[8-K] ATAI Life Sciences N.V. Reports Material Event | ATAI SEC FilingForm 8-K - Stock Titan
Atai Beckley N.V. Announces Breakthrough Therapy Designation for BPL-003 and Positive Phase 2 Results for Treatment-Resistant Depression - Quiver Quantitative
Earnings Flash (ATAI) Atai Beckley N.V. Reports Q3 Revenue $749,000 - MarketScreener
Earnings Flash (ATAI) Atai Beckley Posts Q3 Net Loss $0.28 a Share, vs. FactSet Est of $0.11 Loss - MarketScreener
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
AtaiBeckley (NASDAQ: ATAI) closes approx. $150M offering, funding into 2029 - Stock Titan
AtaiBeckley’s BPL-003 could redefine psychedelics dosing, analysts believe - Proactive Investors
Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant DepressionSlideshow (NASDAQ:ATAI) 2025-11-10 - Seeking Alpha
Atai Beckley Reports Positive Phase 2b Extension Data for Depression Treatment - MarketScreener
Why Atai Life Sciences N.V. (9VC) stock stays undervalued2025 Earnings Impact & Precise Swing Trade Alerts - newser.com
Why Atai Life Sciences N.V. (9VC) stock appears on watchlistsPortfolio Performance Report & Low Drawdown Investment Strategies - newser.com
AtaiBeckley Announces Positive Topline Data from the Phase - GlobeNewswire
Why Atai Life Sciences N.V. (9VC) stock is trending on social media2025 EndofYear Setup & Intraday High Probability Alerts - newser.com
Will Atai Life Sciences N.V. (9VC) stock justify high valuationWeekly Gains Report & Fast Exit Strategy with Risk Control - newser.com
Is Atai Life Sciences N.V. stock poised for growth2025 Earnings Impact & Weekly Market Pulse Updates - newser.com
AtaiBeckley (NASDAQ: ATAI) Shows Added Effect from Second 12 mg Dose at 8 Weeks - Stock Titan
Is Atai Life Sciences N.V. (9VC) stock nearing a technical breakoutJuly 2025 Macro Moves & Daily Growth Stock Tips - newser.com
Will Atai Life Sciences N.V. stock reach all time highs in 2025Trade Ideas & Safe Capital Preservation Plans - newser.com
ATAI BECKLEY NV Insider Trades - Nasdaq
Published on: 2025-11-08 08:57:18 - newser.com
Is Atai Life Sciences N.V. (9VC) stock trading at attractive multiplesPortfolio Value Report & Stock Portfolio Risk Control - newser.com
ATAI Life Sciences Files Prospectus for Share Resale - MSN
[Form 3] ATAI Life Sciences N.V. Initial Statement of Beneficial Ownership - Stock Titan
Will Atai Life Sciences N.V. stock sustain high P E ratios2025 Market WrapUp & Fast Momentum Stock Entry Tips - newser.com
Atai Beckley N.V.: Target Price Consensus and Analysts Recommendations | ATAI | NL0015000DX5 - MarketScreener
Atai Beckley N.V.: Revenue and Earnings Analysts Forecasts Revisions | ATAI | NL0015000DX5 - MarketScreener
[Form 4] ATAI Life Sciences N.V. Insider Trading Activity - Stock Titan
9VC.SG,0P0001MXOV,0 (9VC.SG) Latest Press Releases & Corporate News - Yahoo! Finance Canada
Combining machine learning predictions for Atai Life Sciences N.V.2025 Growth vs Value & Risk Managed Investment Entry Signals - newser.com
Building trade automation scripts for Atai Life Sciences N.V.July 2025 Summary & Daily Price Action Insights - newser.com
Can Atai Life Sciences N.V. stock resist sector downturnsWeekly Earnings Recap & Expert Approved Trade Ideas - newser.com
Why Atai Life Sciences N.V. stock appeals to dividend seekers2025 Top Decliners & Technical Entry and Exit Alerts - newser.com
Will Atai Life Sciences N.V. stock benefit from upcoming earnings reportsJuly 2025 Breakouts & Community Driven Trade Alerts - Fundação Cultural do Pará
Is Atai Life Sciences N.V. stock a defensive play in 2025Inflation Watch & Real-Time Buy Signal Alerts - newser.com
Chart based analysis of Atai Life Sciences N.V. trendsJuly 2025 Chart Watch & Daily Market Momentum Tracking - newser.com
Latham & Watkins Advises atai Life Sciences in Strategic Combination With Beckley Psytech to Form AtaiBeckley - Legal Desire Media and Insights
Will Atai Life Sciences N.V. (9VC) stock test record highs in 2025Exit Point & AI Driven Price Predictions - newser.com
Atai Beckley files prospectus supplement for resale of 5.3 million shares By Investing.com - Investing.com Nigeria
Watkins Advises atai Life Sciences in Strategic Combination With Beckley Psytech to Form AtaiBeckley - Latham & Watkins LLP
Understanding Atai Life Sciences N.V.’s price movementQuarterly Market Review & Precise Trade Entry Recommendations - newser.com
Is Atai Life Sciences N.V. stock recession proofJuly 2025 Update & Accurate Intraday Trade Tips - fcp.pa.gov.br
Atai Beckley N V Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):